Two-Year Therapeutic Efficacy and Safety of Initial Triple Combination of Metformin, Sitagliptin, and Empagliflozin in Drug-Naïve Type 2 Diabetes Mellitus Patients (Diabetes Metab J 2024;48:253-64).
作者信息
Lee Eun Young
机构信息
Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
出版信息
Diabetes Metab J. 2024 Sep;48(5):1005-1007. doi: 10.4093/dmj.2024.0417. Epub 2024 Sep 1.
Abstract
摘要
相似文献
1
Two-Year Therapeutic Efficacy and Safety of Initial Triple Combination of Metformin, Sitagliptin, and Empagliflozin in Drug-Naïve Type 2 Diabetes Mellitus Patients (Diabetes Metab J 2024;48:253-64).二甲双胍、西他列汀和恩格列净初始三联组合用于初治2型糖尿病患者的两年治疗疗效及安全性（《糖尿病与代谢杂志》2024年；48:253 - 64）
Diabetes Metab J. 2024 Sep;48(5):1005-1007. doi: 10.4093/dmj.2024.0417. Epub 2024 Sep 1.
2
Two-Year Therapeutic Efficacy and Safety of Initial Triple Combination of Metformin, Sitagliptin, and Empagliflozin in Drug-Naïve Type 2 Diabetes Mellitus Patients (Diabetes Metab J 2024;48:253-64).二甲双胍、西他列汀和恩格列净初始三联组合用于初治2型糖尿病患者的两年治疗疗效和安全性（《糖尿病代谢杂志》2024年；48:253 - 64）
Diabetes Metab J. 2024 Sep;48(5):1012-1013. doi: 10.4093/dmj.2024.0485. Epub 2024 Sep 1.
3
Comparison Of Efficacy And Safety Profile Of Empagliflozin As A Combination Therapy In Obese Type 2 Diabetic Patients.恩格列净作为联合疗法在肥胖 2 型糖尿病患者中的疗效和安全性比较。
J Ayub Med Coll Abbottabad. 2021 Apr-Jun;33(2):188-191.
4
Comparison of the effects of empagliflozin and sitagliptin, as add-on to metformin, on serum levels of asprosin and metabolic parameters in patients with type 2 diabetes mellitus.比较恩格列净和西他列汀作为二甲双胍的附加疗法对 2 型糖尿病患者血清中 asparosin 水平和代谢参数的影响。
Naunyn Schmiedebergs Arch Pharmacol. 2024 Nov;397(11):9149-9165. doi: 10.1007/s00210-024-03219-z. Epub 2024 Jun 20.
5
Efficacy of Dapagliflozin + Sitagliptin + Metformin Versus Sitagliptin + Metformin in T2DM Inadequately Controlled on Metformin Monotherapy: A Multicentric Randomized Trial.达格列净+西他列汀+二甲双胍与西他列汀+二甲双胍治疗二甲双胍单药治疗控制不佳的2型糖尿病的疗效：一项多中心随机试验
Adv Ther. 2025 Feb;42(2):801-812. doi: 10.1007/s12325-024-03037-y. Epub 2024 Dec 5.
6
Efficacy and tolerability of initial triple combination therapy with metformin, dapagliflozin and saxagliptin compared with stepwise add-on therapy in drug-naïve patients with type 2 diabetes (TRIPLE-AXEL study): A multicentre, randomized, 104-week, open-label, active-controlled trial.在初治的 2 型糖尿病患者中，与逐步加用药物相比，二甲双胍、达格列净和沙格列汀三联疗法的疗效和耐受性：一项多中心、随机、104 周、开放标签、活性对照试验（TRIPLE-AXEL 研究）。
Diabetes Obes Metab. 2024 Sep;26(9):3642-3652. doi: 10.1111/dom.15705. Epub 2024 Jun 10.
7
Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes.恩格列净、西格列汀和二甲双胍的长期安全性及疗效：一项针对2型糖尿病患者的活性对照、平行组、随机、78周开放标签扩展研究。
Diabetes Care. 2013 Dec;36(12):4015-21. doi: 10.2337/dc13-0663. Epub 2013 Nov 1.
8
9
A 52-week efficacy and safety study of enavogliflozin versus dapagliflozin as an add-on to metformin in patients with type 2 diabetes mellitus: ENHANCE-M extension study.一项恩格列净作为 2 型糖尿病患者二甲双胍附加疗法与达格列净比较的 52 周疗效和安全性研究：ENHANCE-M 扩展研究。
Diabetes Obes Metab. 2024 Jun;26(6):2248-2256. doi: 10.1111/dom.15537. Epub 2024 Mar 8.
10
Efficacy and safety of 11 sodium-glucose cotransporter-2 inhibitors at different dosages in type 2 diabetes mellitus patients inadequately controlled with metformin: a Bayesian network meta-analysis.11种不同剂量钠-葡萄糖协同转运蛋白2抑制剂用于二甲双胍控制不佳的2型糖尿病患者的疗效和安全性：一项贝叶斯网络荟萃分析
BMJ Open. 2025 Feb 26;15(2):e088687. doi: 10.1136/bmjopen-2024-088687.
本文引用的文献
1
Two-Year Therapeutic Efficacy and Safety of Initial Triple Combination of Metformin, Sitagliptin, and Empagliflozin in Drug-Naïve Type 2 Diabetes Mellitus Patients.二甲双胍、西格列汀和恩格列净初始三联治疗药物初治 2 型糖尿病的两年疗效和安全性。
Diabetes Metab J. 2024 Mar;48(2):253-264. doi: 10.4093/dmj.2023.0128. Epub 2024 Jan 26.
2
2023 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association.2023 年韩国糖尿病协会糖尿病临床实践指南。
Diabetes Metab J. 2023 Sep;47(5):575-594. doi: 10.4093/dmj.2023.0282. Epub 2023 Sep 26.
3
IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045.国际糖尿病联盟（IDF）糖尿病地图集：2021 年全球、区域和国家糖尿病患病率估算值以及 2045 年预测值。
Diabetes Res Clin Pract. 2022 Jan;183:109119. doi: 10.1016/j.diabres.2021.109119. Epub 2021 Dec 6.
4
Therapeutic efficacy and safety of initial triple combination of metformin, sitagliptin, and lobeglitazone in drug-naïve patients with type 2 diabetes: initial triple study.初治的 2 型糖尿病患者中二甲双胍、西格列汀和罗格列酮三联治疗的疗效和安全性：初始三联研究。
BMJ Open Diabetes Res Care. 2020 Jan;8(1). doi: 10.1136/bmjdrc-2019-000807.
5
Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial.新诊断 2 型糖尿病患者中维格列汀联合二甲双胍早期治疗与二甲双胍单药序贯治疗的血糖耐久性（VERIFY）：一项 5 年、多中心、随机、双盲试验。
Lancet. 2019 Oct 26;394(10208):1519-1529. doi: 10.1016/S0140-6736(19)32131-2. Epub 2019 Sep 18.
6
Prevalence of micro- and macrovascular diabetes complications at time of type 2 diabetes diagnosis and associated clinical characteristics: A cross-sectional baseline study of 6958 patients in the Danish DD2 cohort.2 型糖尿病诊断时微血管和大血管糖尿病并发症的患病率及相关临床特征：丹麦 DD2 队列中 6958 例患者的横断面基线研究。
J Diabetes Complications. 2018 Jan;32(1):34-40. doi: 10.1016/j.jdiacomp.2017.09.010. Epub 2017 Sep 19.
7
Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT): a randomized trial.对于新发糖尿病患者，二甲双胍、吡格列酮和艾塞那肽初始联合治疗比序贯加用治疗更有效。2型糖尿病初始联合治疗的疗效和持久性（EDICT）随机试验结果。
Diabetes Obes Metab. 2015 Mar;17(3):268-75. doi: 10.1111/dom.12417. Epub 2015 Jan 7.
8
Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people.2型糖尿病患者的临床惰性：一项对8万多人的回顾性队列研究。
Diabetes Care. 2013 Nov;36(11):3411-7. doi: 10.2337/dc13-0331. Epub 2013 Jul 22.
9
10-year follow-up of intensive glucose control in type 2 diabetes.2型糖尿病强化血糖控制的10年随访
N Engl J Med. 2008 Oct 9;359(15):1577-89. doi: 10.1056/NEJMoa0806470. Epub 2008 Sep 10.
Zotero 插件